Search Results - "Stefoni, V."

Prognostic impact of pretreatment cell-free DNA concentration in newly diagnosed peripheral T-cell lymphomas by Fardella, E, Zanirato, G, Magni, M, Caldarelli, N, Chiappella, A, Dodero, A, Ljevar, S, Orsucci, L, Re, A, Usai, S V, Stefoni, V, Castellino, C, Rossi, F G, Pinto, A, Carniti, C, Corradini, P

“…Peripheral T-cell lymphomas (PTCLs) have a poor prognosis and, to date, there are no reliable predictive biomarkers of response. In this work we explored the…”
Get full text

Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome by Zinzani, P.L., Venturini, F., Stefoni, V., Fina, M., Pellegrini, C., Derenzini, E., Gandolfi, L., Broccoli, A., Argnani, L., Quirini, F., Pileri, S., Baccarani, M.

“…Peripheral T-cell lymphoma unspecified (PTCLU) and mycosis fungoides (MF) often show resistance to conventional chemotherapy. Gemcitabine should be considered…”
Get full text

First salvage treatment with bendamustine and brentuximab vedotin in Hodgkin lymphoma: a phase 2 study of the Fondazione Italiana Linfomi by Broccoli, A., Argnani, L., Botto, B., Corradini, P., Pinto, A., Re, A., Vitolo, U., Fanti, S., Stefoni, V., Zinzani, P. L.

“…Effective salvage options inducing high complete metabolic response (CMR) rates without significant toxicity are needed for Hodgkin lymphoma (HL) patients…”
Get full text

Gut microbiome in DLBCL patients undergoing first‐line R‐CHOP regimen—The Oncopassport Study by Stefoni, V., Argnani, L., Casadei, B., Musuraca, G., Nanni, L., Pellegrini, C., Broccoli, A., Carella, M., Caldarulo, E., Mammoli, F., Conti, G., Turroni, S., Barone, M., Brigidi, P., Zinzani, P. L.

Get full text

Interaction between gut microbiome and immune checkpoint inhibitor treatment in lymphoma patients: Final results of the MICRO‐LINF study by Casadei, B., Argnani, L., Guadagnuolo, S., Nanni, L., Pellegrini, C., Broccoli, A., Carella, M., Stefoni, V., Conti, G., Turroni, S., Barone, M., Brigidi, P., Zinzani, P. L.

Get full text

The treatment of Burkitt lymphoma with the Berlin‐Frankfurt‐Münster protocol with rituximab and autologous transplantation by Broccoli, A., Argnani, L., Gugliotta, G., Stefoni, V., Pellegrini, C., Casadei, B., Nanni, L., Coppola, P. E., Sutto, E., Cantelli, M., Morigi, A., Bagnato, G., Gentilini, M., Zoli, S., Carella, M., Lolli, G., Zinzani, P. L.

Get full text

Role of autologous stem cell transplantation or salvage chemotherapy in relapsed/refractory classical Hodgkin lymphoma patients after immune checkpoint inhibitors by Pellegrini, C., Casadei, B., Sutto, E., Cantelli, M., Argnani, L., Broccoli, A., Gugliotta, G., Stefoni, V., Nanni, L., Carella, M., Zoli, S., Coppola, P. E., Lolli, G., Morigi, A., Bagnato, G., Gentilini, M., Zinzani, P. L.

Get full text

BEGEV as salvage regimen in first setting for relapsed/refractory classical Hodgkin lymphoma by Carella, M., Argnani, L., Coppola, P. E., Nanni, L., Zoli, S., Cantelli, M., Morigi, A., Gentilini, M., Lolli, G., Bagnato, G., Sutto, E., Gugliotta, G., Casadei, B., Pellegrini, C., Stefoni, V., Broccoli, A., Zinzani, P. L.

Get full text

Single‐agent rituximab as an effective salvage therapy in pre‐treated hairy cell leukemia by Broccoli, A., Argnani, L., Nanni, L., Lolli, G., Stefoni, V., Zoli, S., Cantelli, M., Pellegrini, C., Morigi, A., Gentilini, M., Sutto, E., Gugliotta, G., Coppola, P. E., Casadei, B., Carella, M., Bagnato, G., Zinzani, P. L.

Get full text

Predicting ICANS by means of plasma CAR‐T cell derived extracellular vesicles in patients undergoing infusion of anti‐CD19 CAR‐T cells by Felice, F., Storci, G., Ricci, F., Tazzari, P. L., Matteis, S., Bertuccio, S. N., Rossini, L., Tomassini, E., Dicataldo, M., Laprovitera, N., Barbato, F., Ursi, M., Messelodi, D., Cortelli, P., Guarino, M., Maffini, E., Roberto, M., Dan, E., Sinigaglia, B., Santi, S., Ferracin, M., Pellegrini, C., Stefoni, V., Guadagnuolo, S., Casadei, B., Zinzani, P. L., Bonafe, M., Bonifazi, F.

Get full text

ROMIDEPSIN PLUS CHOP VERSUS CHOP IN PATIENTS WITH PREVIOUSLY UNTREATED PERIPHERAL T‐CELL LYMPHOMA: FINAL ANALYSIS OF THE RO‐CHOP TRIAL by Camus, V., Thieblemont, C., Gaulard, P., Cheminant, M., Casasnovas, R., Ysebaert, L., Damaj, G. L., Guidez, S., Pica, G. M., Kim, W. S., Lim, S. T., Andre, M., Gutiérrez, N., Penarrubia, M. J., Staber, P. B., Trotman, J., Hüttmann, A., Stefoni, V., Rossi, G., Delfau‐Larue, M., Cottereau, A., Itti, E., Li, J., Delarue, R., Leval, L., Morschhauser, F., Bachy, E.

Get full text

Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients by Zinzani, P. L., Tani, M., Fanti, S., Alinari, L., Musuraca, G., Marchi, E., Stefoni, V., Castellucci, P., Fina, M., Farshad, M., Pileri, S., Baccarani, M.

“…Background: It is important to distinguish between responders to standard treatment and non-responders Hodgkin's disease (HD) patients. Patients and Methods:…”
Get full text

BEGEV SALVAGE REGIMEN IN RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA: A REAL‐LIFE EXPERIENCE by Morigi, A., Stefoni, V., Argnani, L., Carella, M., Casadei, B., Lolli, G., Broccoli, A., Pellegrini, C., Nanni, L., Coppola, P. E., Gentilini, M., Bagnato, G., Zinzani, P. L.

Get full text

FIRST SALVAGE TREATMENT WITH BENDAMUSTINE AND BRENTUXIMAB VEDOTIN IN HODGKIN LYMPHOMA: A PHASE 2 STUDY OF FIL ONLUS by Stefoni, V., Broccoli, A., Botto, B., Corradini, P., Pinto, A., Re, A., Vitolo, U., Fanti, S., Argnani, L., Zinzani, P.

Get full text

90Y‐IBRITUMOMAB TIUXETAN IN PATIENTS WITH EXTRA‐NODAL MARGINAL ZONE B‐CELL LYMPHOMA OF MUCOSA ASSOCIATED LYMPHOID TISSUE (MALT LYMPHOMA) – THE ZENO STUDY by Marangon, M., Morigi, A., Casadei, B., Broccoli, A., Nanni, L., Stefoni, V., Argnani, L., Lolli, G., Carella, M., Zinzani, P.

Get full text

MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis: experience on seven patients by Derenzini, E., Fina, M.P., Stefoni, V., Pellegrini, C., Venturini, F., Broccoli, A., Gandolfi, L., Pileri, S., Fanti, S., Lopci, E., Castellucci, P., Agostinelli, C., Baccarani, M., Zinzani, P.L.

“…Adult Langerhans cell histiocytosis (LCH) is a rare disease. The combination of vinblastine and prednisone, given in a 6-month course, is the standard of care…”
Get full text

ROMIDEPSIN‐CHOEP PLUS UP‐FRONT STEM‐CELL TRANSPLANTATION IN PERIPHERAL T‐CELL LYMPHOMA (PTCL): FIRST ANALYSIS OF THE PHASE II FIL‐PTCL13 STUDY by Chiappella, A., Carniti, C., Re, A., Castellino, C., Evangelista, A., Ciancia, R., Orsucci, L., Pinto, A., Usai, S. V., Arcari, A., Ilariucci, F., Rossi, F. G., Benedetti, F., Flenghi, L., Ghiggi, C., Molinari, A. L., Stefoni, V., Volpetti, S., Zilioli, V. R., Ballerini, F., Bruna, R., Cavallo, F., Musuraca, G., Patti, C., Re, F., Tani, M., Varettoni, M., Zanni, M., Dodero, A., Pileri, S. A., Ciccone, G., Corradini, P.

Get full text

A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients by Zinzani, P. L., Tani, M., Fanti, S., Stefoni, V., Musuraca, G., Castellucci, P., Marchi, E., Farsad, M., Fina, M., Pellegrini, C., Alinari, L., Derenzini, E., de Vivo, A., Bacci, F., Pileri, S., Baccarani, M.

“…Background: A prospective, single-arm, open-label, nonrandomized phase II combination chemotherapy with cyclophosphamide, doxorubicin, vincristine, and…”
Get full text

PHASE II FIL‐PTCL13 STUDY OF ROMIDEPSIN‐CHOEP FOLLOWED BY HIGH‐DOSE CHEMOTHERAPY AND TRANSPLANTATION IN UNTREATED PERIPHERAL T‐CELL LYMPHOMAS by Chiappella, A., Carniti, C., Evangelista, A., Re, A., Cabras, M.G., Stefoni, V., Castellino, C., Congiu, A.G., Pinto, A., Zanni, M., Rusconi, C., Molinari, A.L., Ciancia, R., Baldini, L., Nassi, L., Re, F., Tani, M., Ilariucci, F., Cavallo, F., Santoro, A., Volpetti, S., Dodero, A., Pileri, S.A., Ciccone, G., Corradini, P.

Get full text

The role of positron emission tomography (PET) in the management of lymphoma patients by Zinzani, P. L., Magagnoli, M., Chierichetti, F., Zompatori, M., Garraffa, G., Bendandi, M., Gherlinzoni, F., Cellini, C., Stefoni, V., Ferlin, G., Tura, S.

“…Background: Treatment of both Hodgkin's disease (HD) and aggressive non-Hodgkin's lymphoma (NHL) with abdominal presentation at the time of diagnosis is often…”
Get full text